Natalizumab Elan/Biogen

Current Opinion in Investigational Drugs

Volumn 4, Issue 11, 2003, Pages 1354-1362

  Elices, Mariano J ^a  

^a PharmaMar USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN ANTIBODY; ALPHA4BETA7 ANTIBODY; ANTIHISTAMINIC AGENT; BETA INTERFERON; CORTICOSTEROID; DRUG ANTIBODY; GLATIRAMER; IDIOTYPIC ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1 ANTIBODY; VERY LATE ACTIVATION ANTIGEN 4;

ABDOMINAL PAIN; ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANTIBODY PRODUCTION; ARTHRALGIA; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; ENTERITIS; HEADACHE; HUMAN; INFECTION; LEUKOCYTOSIS; LYMPHOCYTOSIS; MULTIPLE SCLEROSIS; MYASTHENIA; NAUSEA; NEUROPROTECTION; NEUTROPHILIA; NONHUMAN; PARESTHESIA; PHARYNGITIS; REBOUND; REVIEW; SIDE EFFECT; SINUSITIS; STRUCTURE ACTIVITY RELATION; URINARY TRACT INFECTION; URTICARIA;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CROHN DISEASE; HALF-LIFE; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0347093659     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 179966 Athena Neurosciences, Inc commences Phase I study with Antegren™. Athena Neurosciences Inc Press Release 1995 June 28
2. 200972 Athena Neurosciences Inc successfully completes Phase I study with Antegren™ and is granted CTX to commence Phase II trial. Athena Neurosciences Inc Press Release 1996 March 05
3. 222518 Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N Nature 1992 356 6364 63-66
4. 222522 A monoclonal antibody to α4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. Kent SJ, Karlik SJ, Rice GP, Horner HC J Magn Reson Imaging 1995 5 5 535-540
5. 223736 Drug development pipeline: Naproxen sodium, natalizumab, A-β-I-196, fampridine, tizanidine and AN-072. Elan Corp Plc Company Communication 1996 October 29
6. 262129 Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Springer TA Cell 1994 76 2 301-314
7. 265753 The pathophysiologic role of α4 integrins in vivo. Lobb RR, Hemler ME J Clin Invest 1994 94 5 1722-1728
8. 265840 Surface expression of α4 integrin by CD4 T-cells is required for their entry into brain parenchyma. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr J Exp Med 1993 177 1 57-68
9. 265842 A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Horner HC J Neuroimmunol 1995 58 1 1-10.
10. 265845 Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. Soilu-Hanninen M, Roytta M, Salmi A, Salonen R J Neuroimmunol 1997 72 1 95-105
11. 269705 Humanization of a mouse antibody against human α-4 integrin: A potential therapeutic for the treatment of multiple sclerosis. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM Hum Antibodies 1997 8 1 3-16
12. 279263 Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Yednock TA Nature 1993 177 57-68
13. 279265 Evidence for a prolonged role of α4 integrin throughout active experimental allergic encephalomyelitis. Keszthelyi E, Karlik S, Hyduk S, Rice GP, Gordon G, Yednock T, Horner H Neurology 1996 47 4 1053-1059
14. 286198 Protein Design Labs grants license under antibody humanization patents to Elan. Protein Design Labs Inc Press Release 1998 May 04
15. 327248 Randomized, double-blind, placebo-controlled trial of recombinant humanized antibody to α4 integrin (Antegren) in active Crohn's disease. Gordon FH, Lai CWY, Hamilton MI, Allison MC, Fouweather M, Donoghue S, Greenlees C, Amlot PL, Srivastava ED, Subhani J, Pounder RE Gastroenterology 1999 Abs 3509
16. 333924 Elan to develop Antegren for the chronic treatment of multiple sclerosis. Elan Corp Plc Press Release 1999 July 26
17. 344447 The effect of anti-α4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Turbidy N Neurology 1999 53 3 466-472
18. 361047 A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M Neurology 1999 52 5 1072-1074
19. 366475 Adhesion molecule expression in inflammatory bowel disease (IBD) patients treated with natalizumab (Antegrentim), a humanised antibody to A4 integrin. Gordon FH, Rana S, Tahami F, Khan K, Amlot PL, Pounder RE Gastroenterology 2000 118 4 Suppl 2 Abs 1857
20. 382577 Global healthcare bulletin. Merrill Lynch Capital Markets 2000 September 1
21. 386933 Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, Newman W, Ringler DJ Gastroenterology 1996 111 5 1373-1380
22. 409094 A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to α4 integrin (Antegren) in moderate to severely active Crohn's disease. Gastroenterology 2001 120 5 Suppl 1 Abs 682
23. 422373 Speciality Pharmaceuticals - Brand-focused companies second quarter round-up. Salomon Smith Barney 2001 September 5
24. 422425 Elan Corp: Delivering. Abn Amro Bank NV USA 2001 April 5
25. 434121 Elan and Biogen begin phase III clinical trials of Antegren™ (natalizumab) in multiple sclerosis and Crohn's disease. Elan Corp Plc Press Release 2001 December 18
26. 441362 A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohns' disease. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE Gastroenterology 2001 121 2 268-274
27. 449588 Canadian phase III clinical trials of Antegren begin in multiple sclerosis. Biogen Inc Press Release 2002 April 26
28. 451645 Pharmacokinetics (PK) and pharmacodynamics (PD) of natalizumab in active Crohn's disease patients. Van Deventer S, Rutgeerts P, Rask Madson J, Shah J, Palmer T, Goldblum R Gastroenterology 2002 122 4 Suppl 1 Abs T1212
29. 460892 Investor relations: Elan strategy and recovery presentation (presentation to shareholders and other stakeholders). Elan Corp Plc Company Presentation 2002 July 31
30. 475303 Clinical Study Results Published in the New England Journal of Medicine Show Promising Data on ANTEGREN (Natalizumab) in the Treatment of Relapsing Forms of Multiple Sclerosis. Biogen Inc, Elan Corp Plc Press Release 2003 January 02
31. 476332 Integrins: Bidirectional, allosteric signalling machines. Hynes RO Cell 2002 110 6 673-687.
32. 478086 Elan reports fourth quarter 2002 and full-year financial results and recovery plan update. Elan Corp Plc Press Release 2003 February 05
33. 488003 Elan first quarter 2003 financial results and recovery plan update. Elan Corp Plc Press Release 2003 April 30
34. 488597 Annual Report 2002: GTC Biotherapeutics. GTC Biotherapeutics Inc Annual Report 2003 March 13
35. 498831 Analysis of Antegren induction clinical trial in Crohn's disease completed. Elan Corp Plc, Biogen Inc Press Release 2003 July 24
36. 498915 Elan and Biogen joint conference call. Elan Corp Plc, Biogen Inc Company Presentation 2003 July 24
37. 503587 Leukocyte polarisation in cell migration and immune interactions. Sanchez-Madrid F, Del Pozo MA Embo J 1999 18 3 501-511
38. 503595 α4 Integrins as therapeutic targets in autoimmune disease. Von Andrian UH, Engelhardt B N Engl J Med 2003 348 1 68-72
39. 503604 A controlled trial of natalizumab for relapsing multiple sclerosis. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miskiel KA, O'Connor PW, International Natalizumab Multiple Sclerosis Trial Group N Engl J Med 2003 348 1 15-23
40. 503611 Natalizumab for active Crohn's disease. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S, Natalizumab Pan-European Study Group N Engl J Med 2003 348 1 24-32
41. 503638 The development of experimental autoimmune encephalomyelitis in the mouse requires α4 integrin but not α4β7 integrin. Engelhardt B, Laschinger M, Schulz M, Samulowitz U, Vestweber D, Hoch G J Clin Invest 1998 102 12 2096-2105
42. 503642 Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno C, Nazareno R, Kuchroo VK, Miller SD J Clin Invest 2001 107 8 995-1006.
43. 503646 Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. Podolsky DK, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, DeBeaumont M J Clin Invest 1993 92 1 372-380.
44. 503662 VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Sans M, Panes J, Ardite E, Elizalde JI, Arce Y, Elena M, Palacin A, Fernandez-Checa JC, Anderson DC, Lobb R, Pique JM Gastroenterology 1999 116 4 874-883
45. 503670 Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K Gastroenterology 2001 121 6 1428-1436
46. 504220 Elan Corp plc: 2002 Annual report. Elan Corp Plc Annual Report 2003 September 05
47. 505132 Natalizumab for active Crohn's disease. Lew EA, Stoffel EM N Engl J Med 2003 348 16 1599
48. 505134 Natalizumab for relapsing multiple sclerosis. Chaudhuri A, Behan PO N Engl J Med 2003 348 16 1598-1599
49. 511410 Elan Corp plc: Pipeline update/outlook. Larson A et al. Salomon Smith Barney 2003 February 06
50. 511412 Springer Semin Immunopathol Elices MJ (Ed) 1995